Assessing the economic challenges posed by orphan drugs: A response to McCabe et al. [2]

International Journal of Technology Assessment in Health Care

Volumn 23, Issue 3, 2007, Pages 401-404

  Drummond, Michael F ^a   Wilson, David A ^b   Kanavos, Panos ^c   Ubel, Peter A ^d   Rovira, Joan ^e  

^a UNIVERSITY OF YORK   (United Kingdom)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN; ORPHAN DRUG; RECOMBINANT ENZYME; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; UNCLASSIFIED DRUG;

COST EFFECTIVENESS ANALYSIS; DRUG COST; FETISHISM; GENETICS; GENOME; GLYCOGEN STORAGE DISEASE TYPE 2; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; LETTER; PATIENT CARE; QUALITY ADJUSTED LIFE YEAR; SOCIAL PSYCHOLOGY;

EID: 34250719095     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462307071024     Document Type: Letter

References (5)

1. Blundell R, Costa Dias M. Evaluation methods of non-experimental data. Fiscal Studies. 2000;21:427-468.
2. Commission of the European Communities. Commission Staff Working Document on the experience acquired as a result of the application of Regulation No. 141/2000 on orphan medicinal products and account of the public health benefits obtained. 20.6.2006, SEC(2006) 832. Brussels: Commission of the European Communities.
3. European Parliament and the Council of the European Union. Regulation EC No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities.
4. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making. Evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics. 2001:19:1103-1109.
5. Ministere delegue a la recherché. French National Plan for Rare Diseases 2005-2008. Ensuring equity in the access to diagnosis, treatment and provision of care. 20 November 2004. Paris: Ministere delegue a la recherché.